Moleculin Biotech, Inc.(NASDAQ : MBRX)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Pharmaceuticals Major
|JNJ||Johnson & Johnson||-0.19%||177.17||0.7%||$1337.76m|
|MRK||Merck & Co., Inc.||-0.07%||91.11||0.7%||$1167.06m|
|LLY||Eli Lilly & Co.||-1.48%||319.45||1.1%||$1030.26m|
|BMY||Bristol-Myers Squibb Co.||-1.49%||75.86||1.0%||$992.94m|
|TPTX||Turning Point Therapeutics, Inc.||-0.12%||75.16||0.0%||$287.74m|
|HZNP||Horizon Therapeutics Plc||-0.21%||79.59||5.4%||$161.46m|
|MRTX||Mirati Therapeutics, Inc.||3.49%||69.47||1.6%||$151.82m|
|BHVN||Biohaven Pharmaceutical Holding Co. Ltd.||-0.27%||145.32||0.0%||$141.94m|
|ALNY||Alnylam Pharmaceuticals, Inc.||0.96%||147.25||8.1%||$141.86m|
Moleculin Biotech, Inc. is a clinical stage pharmaceutical company, which engages in the development of treatments for highly resistant cancers and viruses. Its clinical stage drugs include Annamycin, an Anthracycline being studied for the treatment of relapsed or refractory acute myeloid leukemia (AML), and WP1066, an Immune/Transcription Modulator targeting brain tumors, pancreatic cancer, and AML. The company was founded by Walter V. Klemp, Donald H. Picker, and Waldemar Priebe on July 28, 2015 and is headquartered in Houston, TX.